# Date and Time: 28 September 2009 (Time: 10:00 – 16:00)

Minutes: Confirm Guideline Develo	ned opment Group Meeting	Sedation for diagnostic and therapeutic procedures in children and young people	
Place:	NCGC, 4th Floor, c/o Reg		
	338 Euston Rd, London NW1 3BT		
Present:	Nick Girdler (Professor of S Susan King (Consultant Ra Christina Liossi (Senior Lec Liz McArthur (Lead Clinical	tal Practitioner) (PA) aediatric Anaesthetist) (PC) nsultant Paediatric Gastroenterologist) (NC) dedation Dentistry) (NG) diologist) (SK) cturer in Health Psychology) (CL) Nurse Specialist) (LM) Consultant, Emergency Care) (HM) arer Representative) (FP) A&E Medicine) (DW) arer Representative) (MW) operating Officer) (IB) arch Fellow) (EC) nomist) (AA) n Fellow) (NMa) ellow) (KDM)	

## In attendance:

NICE Staff:	
None	

#### **Observers:**

Taryn Krause (TK)	Jill Parnham (JP)	
-------------------	-------------------	--

## Notes

- MS welcomed the group to the 8<sup>th</sup> meeting of this GDG. Apologies were received from Neil Morton and Sue Latchem. The Chair asked all GDG members to declare any relevant conflicts of interest. All declared that they knew of no personal specific, personal nonspecific, non-personal specific or non-personal non-specific interest in the development of this guideline.
- 2. The minutes of the last meeting of this group were agreed as a true and accurate account of the meeting.
- 3. An update was then given to the GDG on progress since the last meeting.

## Notes

- 4 The Chair gave presentation on the clinical interpretation of the evidence for Midazolam, Ketamine and Nitrous Oxide and took questions and comments from the group.
- 5 The Chair introduced Ian Bullock (Chief Operating Officer at NCGC) and Christina Liossi (Senior Lecturer in Health Psychology) who gave an update on the psychological preparation for sedation and took questions from the group.
- 6 The Chair introduced Ian Bullock (Chief Operating Officer at NCGC) and Liz McArthur (Lead Clinical Nurse Specialist), who gave an update on the survey on children's opinion and took questions from the group.
- 7 The Chair introduced the research fellow Nahara Martinez, who gave presentation on the evidence of efficacy and safety for Triclofos sodium.

The Chair thanked NM for her presentation. The GDG then discussed the clinical interpretation of evidence for Triclofos sodium.

8 The Chair introduced the research fellow Nahara Martinez, who gave presentation on the evidence of efficacy and safety for Propofol.

The Chair thanked NM for her presentation. The GDG then discussed the clinical interpretation of evidence for Propofol.

9 The Chair introduced the research fellows Nahara Martinez Kathy De Mott, who gave presentation on the evidence of efficacy and safety for Opioids.

The Chair thanked NM and KDM for their presentation. The GDG then discussed the clinical interpretation of evidence for Opioids.

10 The Chair introduced the research fellow Emily Crowe, who gave presentation on the evidence of efficacy and safety for Sevofluorane.

The Chair thanked EC for her presentation. The GDG then discussed the clinical interpretation of evidence for Sevofluorane.

- 11 SR presented the work-plan for the next GDG meeting. The GDG will discuss the draft recommendations based on the evidence presented. The health economist will present the first draft of the economic method. The technical team will present the evidence for the sedation sparing questions.
- 12 The Chair closed the meeting and thanked everyone for attending.

#### Date, time and venue of the next meeting

Monday 2 November 2009 (Time: 10.00 – 16:00) at NCGC, 4th Floor, c/o Regus (3rd Floor), 338 Euston Rd, London NW1 3BT